May 23, 2023

ALLAS, May 23, 2023 /PRNewswire/ — The Association of Diversity in Clinical Trials (AOD), a diversity-focused organization whose mission is to set standards and best practices for the clinical trials industry to improve the representation of diverse participants in clinical trials announces a new supporting partner, DROX Health Science. DROX is a contract research organization (CRO) headquartered in Miami with locations in Mexico and Germany that offers comprehensive clinical research management services.

Principal CEO of DROX Health Science, Marco Cid, shared, “This partnership is a significant step in bringing awareness to an issue that affects everyone globally. I’m a firm believer that Mexico is a world player in the development and research of new therapeutic options. By partnering with the AOD, we’re able to address the longstanding issue of inadequate representation in clinical trials and hope to influence the outcome of trials around the world.”

CEO and Chief Diversity Officer of the AOD, Diana Foster, Ph.D., states, “The CID Group has been at the forefront of issues affecting clinical trials globally for a decade and the commitment they are making to the AOD speaks to their recognition of the importance of diverse representation in clinical trials.”

About The Association of Diversity in Clinical Trials
The AOD is comprised of partners who are committed to the mission of the organization; Our Mission is to Establish Standards and Best Practices for the Clinical Trials Industry to Improve the Representation of Diverse Participants in Clinical Trials Through the Development, Integration, and Monitoring of Quality and Consistent Diversity Methodology Across the Research Industry. For information about The Association of Diversity in Clinical Trials and to view the partnership levels, visit our website at www.associationofdiversity.org.

About DROX Health Sciences
DROX Health Science is a Contract Research Organization (CRO) with comprehensive clinical research service experience and a front runner in recruiting and retaining patients from diverse backgrounds. DROX specializes in selecting high-performing clinical research sites. They are leaders in the field with over 10 years of experience in several therapeutic areas. DROX has an international presence, ethical compliance, a strong regulatory track record, a robust quality data capture and clinical research management framework, aligned with the International Conference on Harmonization (ICH). Visit their website to learn more, www.droxhealth.com.

Jeremy Mitchell, MBA
Director, Business Development
The Association of Diversity in Clinical Trials  
[email protected]

SOURCE The Association of Diversity in Clinical Trials

Diana L. Foster, Ph.D

CEO and Chief Diversity Officer for TOTAL Diversity Clinical Trial Management

Diana L. Foster, Ph.D., is the CEO and Chief Diversity Officer for TOTAL Diversity Clinical Trial Management, a full-service Diversity Organization whose mission is to enhance diversity and inclusion in clinical research trials. Foster has served as the Vice President of Diversity, Equity, and Inclusion for the Society of Clinical Research Sites (SCRS) since 2016. She also held a position as the Vice President of Strategy and Development for SCRS originating programs such as the Global Impact Partner Programs and many other industry supported initiatives.

Foster is a thought-leader and sought-after expert in diversity and clinical site best practices. She is the author of the Diversity Site Assessment Tool and has published numerous research papers on the topic. Over the past two decades, she has addressed audiences across the world, published multiple papers and articles, and written five authoritative industry books including Global Issues in Patient Recruitment and Retention.

Jerome Adams, M.D.

Chairman of the Board for TOTAL Diversity Clinical Trial Management

Dr. Adams also currently serves as Executive Director of Health Equity Initiatives at Purdue University. He formerly served as the 20th United States Surgeon General and as a member of the President’s COVID-19 task force, where he was at the forefront of America’s most pressing health challenges throughout the pandemic, including working with companies to increase diversity in vaccine trials.

As the Chairman of the Board for TOTAL Diversity, Dr. Adams provides his in-depth knowledge of patient perspectives and industry views on diversity to create sustainable solutions and best practices to establish more diverse representation in clinical trials.